X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, Lava will receive milestone payment for the lead product SGN-EGFRd2 (PF-08046052), which is being evaluated for the treatment of Colorectal Neoplasms, Non-Small-Cell Lung Carcinoma and Squamous Cell Carcinoma of Head and Neck.
Lead Product(s): PF-08046052
Therapeutic Area: Oncology Product Name: SGN-EGFRd2
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $700.0 million Upfront Cash: $50.0 million
Deal Type: Agreement March 05, 2024
Details:
The collaboration aims to evaluate Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in combination with LAVA-1207, a Gammabody® designed to target the PSMA to trigger the potent and preferential killing of PSMA-positive tumor cells, in patients with mCRPC.
Lead Product(s): LAVA-1207,Pembrolizumab
Therapeutic Area: Oncology Product Name: LAVA-1207
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 25, 2024
Details:
Under the collaboration, Janssen has chosen a lead gamma-delta T-cell engager bispecific antibody candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings for the treatment of cancer.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2023
Details:
LAVA-1207 is a Gammabody™ that conditionally activates Vgamma9 Vdelta2 T cells upon crosslinking to PSMA to trigger the potent and preferential killing of PSMA-positive tumor cells, including metastatic castration-resistant prostate cancer.
Lead Product(s): LAVA-1207
Therapeutic Area: Oncology Product Name: LAVA-1207
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
LAVA-051, is a Gammabody™ that targets CD1d-expressing tumors,uniquely activates both Vγ9Vδ2 T cells as well as invariant natural killer T cells, which represent another conserved immune effector cell population, in a target-dependent manner.
Lead Product(s): LAVA-051
Therapeutic Area: Oncology Product Name: LAVA-051
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales.
Lead Product(s): LAVA-1223
Therapeutic Area: Oncology Product Name: LAVA-1223
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Seagen
Deal Size: $700.0 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement September 26, 2022
Details:
LAVA-051 is a humanized Gammabody™ designed to activate both Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and type 1 NKT cells to kill CD1d-expressing tumor cells.
Lead Product(s): LAVA-051
Therapeutic Area: Oncology Product Name: LAVA-051
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
The dose-escalation data demonstrated a favorable safety profile to date and early encouraging signs of potential anti-tumor activity of LAVA-051, as well as a desirable PK-PD profile, in patients with chronic lymphocytic leukemia and multiple myeloma.
Lead Product(s): LAVA-051
Therapeutic Area: Oncology Product Name: LAVA-051
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
LAVA-051, is a Gammabody that targets CD1d-expressing tumors, demonstrated efficacy and safety in a variety of preclinical models,it uniquely activates both Vγ9Vδ2 T cells as well as iNKT cells, which represent another conserved immune effector cell population.
Lead Product(s): LAVA-051
Therapeutic Area: Oncology Product Name: LAVA-051
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
LAVA-051, a Gammabody designed to activate both Vgamma9 Vdelta2 T cells and type 1 NKT cells to kill CD1d-expressing tumor cells, preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome.
Lead Product(s): LAVA-051
Therapeutic Area: Oncology Product Name: LAVA-051
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
